Evidence map›Paper›PMID 42005278›Full record

ArticleNeuroimage. Reports2026

A longitudinal and explainable 2.5D deep learning framework for Alzheimer's disease progression using ADNI MRI.

Soegianto Soelistiono

Abstract read
In one paragraph

Article in Neuroimage. Reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Soegianto SoelistionoUniversitas Airlangga, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early identification of Alzheimer's disease (AD) and its prodromal stage, mild cognitive impairment (MCI), is important for timely clinical assessment and disease management. Structural T1-weighted magnetic resonance imaging (MRI) captures macroscopic neurodegenerative changes associated with disease progression; however, developing deep learning models that are both methodologically rigorous and clinically interpretable remains challenging. This study presents an explainable deep learning framework for longitudinal classification of cognitively normal (CN), MCI, and AD subjects using MRI data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). A two-and-a-half-dimensional (2.5D) convolutional neural network based on a modified ResNet-18 architecture was used to incorporate contextual information from adjacent sagittal slices while remaining computationally efficient. To preserve longitudinal validity and reduce potential information leakage, multiple follow-up visits per subject were included and a strict subject-level data splitting strategy was adopted. Under this evaluation protocol, the proposed model achieved moderate classification performance, highlighting the difficulty of three-class longitudinal neurodegenerative disease classification under a stringent split design. To further examine the effect of split level, we additionally evaluated the same framework using a scan-level splitting strategy. In our implementation, scan-level splitting did not produce a substantial performance improvement, supporting the use of subject-level splitting primarily as a methodological choice for longitudinal validity. To enhance transparency, Gradient-weighted Class Activation Mapping (Grad-CAM) was used to interpret model predictions. The resulting explanations showed plausible temporo-frontal attention patterns in correctly classified AD cases and more heterogeneous responses in MCI cases. Overall, this work demonstrates that combining longitudinal MRI analysis with explainable deep learning under a rigorous evaluation framework can provide an interpretable and reproducible baseline for Alzheimer's disease research. By jointly emphasizing interpretability, temporal consistency, and evaluation validity, the proposed framework contributes toward the development of more trustworthy AI methods in neuroimaging, while also highlighting the remaining challenges in robust AD classification.

Indexed as

2.5D deep learningADNIAlzheimer’s diseaseExplainable AI (XAI)Grad-CAMLongitudinal analysisMRINeuroimaging

Identifiers

PMID42005278
PMCPMC13085064

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.